Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of guselkumab + golimumab vs monotherapy in moderately to severely active Crohn's disease
2021-003314-39Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab and golimumab in Crohn's disease (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 48 and Endoscopic response at Week 48. Started Aug 2022; status: active.
02
Drugs
guselkumabgolimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-003314-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003314-39.